A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.
REGENXBIO (RGNX) stock plunges after FDA clinical hold on RGX-111/RGX-121 gene therapies over a tumor case. Read more here.
Jan 28 (Reuters) - Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its ...
A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...
REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to ...
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...
An AAV vector genome integration event associated with PLAG1 overexpression was identified in a preliminary analysis of the resected tumor.
REGENXBIO Inc. today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler ...
The company said that the FDA hold has impacted two experimental gene therapies, RGX-111 and RGX-121. ・REGENXBIO added that ...
Stocktwits on MSN
RGNX shares pare losses as Wall Street dismisses gene therapy clinical hold spurred selloff as an overreaction
Leerink said the premarket selloff in shares underscores the degree of surprise on the news, feeding into the "FDA ...
Investing.com -- REGENXBIO Inc. (NASDAQ:RGNX) stock fell 28% Wednesday after the FDA placed clinical holds on two of its ...
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results